PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project-Reference-Cited by-同舟云学术

PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project

Published:2018-09 Issue:9 Volume:13 Page:1302-1311
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Tsao Ming Sound,Kerr Keith M.,Kockx Mark,Beasley Mary-Beth,Borczuk Alain C.,Botling Johan,Bubendorf Lukas,Chirieac Lucian,Chen Gang,Chou Teh-Ying,Chung Jin-Haeng,Dacic Sanja,Lantuejoul Sylvie,Mino-Kenudson Mari,Moreira Andre L.,Nicholson Andrew G.,Noguchi Masayuki,Pelosi Giuseppe,Poleri Claudia,Russell Prudence A.,Sauter Jennifer,Thunnissen Erik,Wistuba Ignacio,Yu Hui,Wynes Murry W.,Pintilie Melania,Yatabe Yasushi,Hirsch Fred R.

Funder

IHC

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference22 articles.

1. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations;Gong;J Immunother Cancer,2018

2. Pointed progress in second-line advanced non-small-cell lung cancer: the rapidly evolving field of checkpoint inhibition;Melosky;J Clin Oncol,2016

3. Immune checkpoint inhibitors in advanced non-small cell lung cancer;Assi;Cancer,2018

4. Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non-small-cell lung cancer;Buttner;J Clin Oncol,2017

5. PD-L1 expression in lung cancer;Yu;J Thorac Oncol,2016

Cited by 626 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antithetical impacts of deleterious LRP1B mutations in non-squamous and squamous NSCLCs on predicting benefits from immune checkpoint inhibitor alone or with chemotherapy over chemotherapy alone: retrospective analyses of the POPLAR/OAK and CHOICE-01 trials;Science China Life Sciences;2024-09-12

2. Pulmonary Cytopathology;Surgical Pathology Clinics;2024-09

3. Immunohistochemistry for prediction of response to immunotherapy;Diagnostic Histopathology;2024-09

4. Integrated diagnostics, complex biomarkers, and a new frontier for tissue pathology;Histopathology;2024-08-29

5. The prognostic value of programmed death-ligand 1 (PD-L1) expression in resected colorectal cancer without neoadjuvant therapy - differences between antibody clones and cell types;BMC Cancer;2024-08-26